Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R.J. Farah

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Related publications

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib + Chemoimmunotherapy (Cit) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-Nhl) in Children (Sparkle Trial): Initial Safety, Pk, and Efficacy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy